Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Immuneering Corporation (IMRX) PT Lowered to $1.50 at Jefferies
May 8, 2024 7:39 AM EDTJefferies analyst Michael Yee lowered the price target on Immuneering Corporation (NASDAQ: IMRX) to $1.50 (from $3.00) while maintaining a Hold rating.
The analyst comments "IMRX reported the Q with no surprises and reiterated key timelines for two data readouts coming in H2:... More
